B cells as key player in shaping anti-tumor immune response
02 / 20 / 2020
B cells to the forefront of cancer immunotherapy
02 2020
Scientific communications
02 2020
Last call to take a place in our next in vivo shuttle session
02 / 11 / 2020
Due to the great success of the registration to our shuttle session - which will be held by mid-march - we are pleased to announce, to all who would still be interested, the availability of newly added seats that can be run on a selection of syngeneic tumor mouse models, ie. EMT6 breast cancer CT26 colon cancer and MCA205 sarcoma.
01 2020
New in vitro Shuttle Session: M2 Macrophage Suppression Assay
01 / 07 / 2020
Initiate the new year with our next in vitro shuttle session on our validated M2 macrophage suppression assay, which will take place by early February – thereby providing an opportunity to timely and cost-effectively assess novel immunotherapeutics.
01 2020
Featured model - Orthotopic glioblastoma mouse model
01 / 07 / 2020
Our syngeneic glioma mouse model, based on the intracranial inoculation of Luc2-expressing GL261 cells and bioluminescence imaging for tumor growth monitoring, represents a suitable tool for chemo- and immunotherapy assessment. It closely mimics the human disease in terms of tumor progression and anti-tumor response, and recapitulates glioblastoma characteristic features including among others tumor immune cell infiltration and tumor-induced immunosuppression.
Model responsiveness to standard Temozolomide and immune checkpoint inhibitors i.e. anti-CTLA4, anti-PD1, and anti-PDL1 antibodies, makes it well-suited for testing candidate compounds for their efficacy, as single agents and/or in combination, in promoting anti-tumor activity.
12 2019
Explicyte poster at ESMO IO Congress 2019
12 / 17 / 2019
"Comprehensive assessment of anti-tumor PDL1 blockade effect in a sarcoma mouse model"
12 2019
Explicyte is proud to be a certified Nanostring partner - Let’s start the Digital Spatial Profiling revolution together
12 / 08 / 2019
To deal with this level of complexity, it’s therefore critical to benefit from technological platform allowing for specific investigation in compartments of interest (eg. tumor vs stroma). Thanks to the GeoMx® platform (Nanostring Inc.), which combines the spatial resolution of immunohistofluorescence with the high-plex gene/protein expression analysis, the Digital Spatial Profiling (DSP) revolution has started.
11 2019
Antibody-dependent cell-mediated cytotoxicity (ADCC) assay for in vitro testing
11 / 21 / 2019
See our case study below or download our white paper!
Many cells of the innate immunity work in concert with the adaptive immune system to effectively afford protection.
10 2019
In vivo syngeneic tumor models for novel drug assessment and MoA deciphering in a cost-saving way
10 / 09 / 2019
How about an opportunity to assess your compounds in a comprehensive and cost-effective manner?
09 2019
Involvement of CD8 T cells in the tumor growth control and in the response to PD1 and PDL1 antibodies
09 / 12 / 2019
Immunotherapy-based anti-cancer strategies such as immune checkpoint inhibitors promote antitumor immune response driven by the mobilization of effector immune cell activity and/or reversal of immunosuppressive mechanisms.
06 2019
In vitro assessment of functional response to PD1 blockade
06 / 27 / 2019
Relying on our validated in vitro immune cell activation assay based on the HTRF quantitation of key cytokine release, we recently documented functional characterization of PD1 blockade.